Share Price and Basic Stock Data
Last Updated: October 16, 2025, 6:44 pm
| PEG Ratio | 1.23 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Chandra Bhagat Pharma Ltd operates in the pharmaceuticals sector and has shown a notable increase in sales over recent quarters. The company reported sales of ₹119.26 Cr for the quarter ending September 2023, a significant rise from ₹75.40 Cr in March 2023 and ₹44.27 Cr in September 2022. This growth trajectory reflects a robust recovery, particularly when compared to the sales of ₹50.93 Cr in March 2022. The annual sales figures also demonstrate a consistent upward trend, with ₹119.67 Cr recorded for the fiscal year ending March 2023, up from ₹94.04 Cr in the previous fiscal year. However, the company anticipates a decline in sales to ₹86.72 Cr for March 2025, indicating potential volatility. The operating profit margin (OPM) has faced challenges, reported at -1.19%, suggesting that while revenue is increasing, cost management remains an issue. The company’s ability to convert sales into profit will be critical in determining its long-term sustainability.
Profitability and Efficiency Metrics
Chandra Bhagat Pharma Ltd’s profitability metrics have raised concerns, particularly with the reported operating profit margin (OPM) of -1.19%. This negative margin indicates that the company’s operational costs are exceeding its earnings. The net profit for the quarter ending September 2023 stood at ₹0.63 Cr, reflecting a slight increase from ₹0.54 Cr in March 2023. However, this is overshadowed by the company’s overall low return on equity (ROE) of 2.41% and return on capital employed (ROCE) of 6.00%, which are both below industry averages. The interest coverage ratio (ICR) of 2.09x suggests that while the company is able to cover its interest obligations, the thin margin leaves little room for error. The cash conversion cycle of 110.17 days further indicates inefficiencies in managing receivables and inventory, which could strain liquidity if not addressed promptly.
Balance Sheet Strength and Financial Ratios
The balance sheet of Chandra Bhagat Pharma Ltd reflects a cautious financial position, with total borrowings reported at ₹20.86 Cr against reserves of ₹22.42 Cr, indicating a manageable debt level. The debt-to-equity ratio stands at 0.69, suggesting that the company is using a moderate level of debt to finance its operations. The current ratio of 1.41 indicates that the company has sufficient short-term assets to cover its liabilities, which is a positive sign for liquidity. However, the declining trend in net profit margins, which stood at 0.98% in March 2025, raises questions about the company’s operational efficiency. The price-to-book value ratio of 1.32x reflects a market valuation that is slightly above book value, implying cautious investor sentiment. A high enterprise value (₹59.68 Cr) relative to net operating revenue further emphasizes the need for improved profitability to justify its valuation in the marketplace.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Chandra Bhagat Pharma Ltd indicates a strong promoter presence, with promoters holding 71.20% of the equity as of March 2025. This substantial stake may provide stability and confidence in management decisions. However, foreign institutional investors (FIIs) hold only 0.61%, and domestic institutional investors (DIIs) have no stake, suggesting limited institutional interest in the company. The public shareholding stands at 28.18%, with a total of 316 shareholders, indicating a relatively small retail investor base. The trend of increasing promoter shareholding from 68.24% in March 2023 to 71.20% in March 2025 may reflect management’s confidence in the company’s future. However, the lack of institutional backing could be a concern, as it often signifies a lack of broader market confidence. The company needs to attract more diverse investors to enhance its market credibility.
Outlook, Risks, and Final Insight
If margins sustain and operational efficiencies improve, Chandra Bhagat Pharma Ltd could potentially leverage its growing sales to enhance profitability. However, the risks remain significant, particularly with the negative operating profit margin and low ROE. The company’s reliance on a narrow promoter base and limited institutional investment could hinder its growth prospects. Additionally, the ongoing volatility in sales, projected to decline in March 2025, poses a risk to financial stability. If the company can effectively manage its operational costs and improve its cash conversion cycle, it may achieve better financial health. Strategic initiatives aimed at enhancing product offerings and expanding market reach could also bolster investor confidence. Ultimately, the company’s ability to navigate these challenges will dictate its long-term success in the competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Chandra Bhagat Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 247/84.3 | 34.4 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,930 Cr. | 452 | 465/192 | 111 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 37.1 Cr. | 50.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.6 Cr. | 20.9 | 29.1/17.0 | 31.9 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,852.62 Cr | 1,184.59 | 50.21 | 194.36 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22.36 | 48.33 | 43.15 | 50.93 | 44.27 | 75.40 | 119.26 | 102.11 | 64.92 | 21.80 |
| Expenses | 20.71 | 46.67 | 41.53 | 49.87 | 43.24 | 73.60 | 124.26 | 104.15 | 66.11 | 22.06 |
| Operating Profit | 1.65 | 1.66 | 1.62 | 1.06 | 1.03 | 1.80 | -5.00 | -2.04 | -1.19 | -0.26 |
| OPM % | 7.38% | 3.43% | 3.75% | 2.08% | 2.33% | 2.39% | -4.19% | -2.00% | -1.83% | -1.19% |
| Other Income | 0.02 | 0.46 | 0.47 | 1.15 | 0.60 | 0.19 | 7.01 | 4.32 | 3.07 | 2.45 |
| Interest | 1.62 | 1.86 | 1.45 | 1.63 | 1.04 | 1.15 | 0.66 | 0.73 | 0.85 | 1.10 |
| Depreciation | 0.01 | 0.02 | 0.06 | 0.06 | 0.05 | 0.22 | 0.43 | 0.21 | 0.41 | 0.54 |
| Profit before tax | 0.04 | 0.24 | 0.58 | 0.52 | 0.54 | 0.62 | 0.92 | 1.34 | 0.62 | 0.55 |
| Tax % | 25.00% | 33.33% | 24.14% | 30.77% | 31.48% | 14.52% | 31.52% | 33.58% | -11.29% | 69.09% |
| Net Profit | 0.03 | 0.16 | 0.43 | 0.36 | 0.37 | 0.54 | 0.63 | 0.90 | 0.68 | 0.17 |
| EPS in Rs | 0.04 | 0.21 | 0.57 | 0.48 | 0.49 | 0.72 | 0.83 | 1.19 | 0.90 | 0.23 |
Last Updated: May 31, 2025, 6:33 am
Below is a detailed analysis of the quarterly data for Chandra Bhagat Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 21.80 Cr.. The value appears to be declining and may need further review. It has decreased from 64.92 Cr. (Sep 2024) to 21.80 Cr., marking a decrease of 43.12 Cr..
- For Expenses, as of Mar 2025, the value is 22.06 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 66.11 Cr. (Sep 2024) to 22.06 Cr., marking a decrease of 44.05 Cr..
- For Operating Profit, as of Mar 2025, the value is -0.26 Cr.. The value appears strong and on an upward trend. It has increased from -1.19 Cr. (Sep 2024) to -0.26 Cr., marking an increase of 0.93 Cr..
- For OPM %, as of Mar 2025, the value is -1.19%. The value appears strong and on an upward trend. It has increased from -1.83% (Sep 2024) to -1.19%, marking an increase of 0.64%.
- For Other Income, as of Mar 2025, the value is 2.45 Cr.. The value appears to be declining and may need further review. It has decreased from 3.07 Cr. (Sep 2024) to 2.45 Cr., marking a decrease of 0.62 Cr..
- For Interest, as of Mar 2025, the value is 1.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.85 Cr. (Sep 2024) to 1.10 Cr., marking an increase of 0.25 Cr..
- For Depreciation, as of Mar 2025, the value is 0.54 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.41 Cr. (Sep 2024) to 0.54 Cr., marking an increase of 0.13 Cr..
- For Profit before tax, as of Mar 2025, the value is 0.55 Cr.. The value appears to be declining and may need further review. It has decreased from 0.62 Cr. (Sep 2024) to 0.55 Cr., marking a decrease of 0.07 Cr..
- For Tax %, as of Mar 2025, the value is 69.09%. The value appears to be increasing, which may not be favorable. It has increased from -11.29% (Sep 2024) to 69.09%, marking an increase of 80.38%.
- For Net Profit, as of Mar 2025, the value is 0.17 Cr.. The value appears to be declining and may need further review. It has decreased from 0.68 Cr. (Sep 2024) to 0.17 Cr., marking a decrease of 0.51 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.23. The value appears to be declining and may need further review. It has decreased from 0.90 (Sep 2024) to 0.23, marking a decrease of 0.67.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 48.01 | 61.13 | 79.84 | 89.79 | 97.06 | 106.28 | 93.97 | 70.70 | 94.04 | 119.67 | 221.37 | 86.72 |
| Expenses | 46.18 | 58.13 | 76.42 | 85.41 | 92.47 | 101.69 | 90.85 | 67.02 | 91.20 | 116.33 | 228.41 | 88.14 |
| Operating Profit | 1.83 | 3.00 | 3.42 | 4.38 | 4.59 | 4.59 | 3.12 | 3.68 | 2.84 | 3.34 | -7.04 | -1.42 |
| OPM % | 3.81% | 4.91% | 4.28% | 4.88% | 4.73% | 4.32% | 3.32% | 5.21% | 3.02% | 2.79% | -3.18% | -1.64% |
| Other Income | 0.64 | 0.31 | 0.38 | 0.49 | 0.67 | 0.44 | 0.44 | 0.48 | 1.62 | 0.29 | 11.33 | 5.49 |
| Interest | 1.88 | 2.35 | 2.83 | 3.81 | 3.67 | 4.09 | 3.11 | 3.76 | 3.24 | 2.20 | 1.39 | 1.95 |
| Depreciation | 0.17 | 0.26 | 0.24 | 0.14 | 0.06 | 0.05 | 0.03 | 0.12 | 0.12 | 0.27 | 0.64 | 0.95 |
| Profit before tax | 0.42 | 0.70 | 0.73 | 0.92 | 1.53 | 0.89 | 0.42 | 0.28 | 1.10 | 1.16 | 2.26 | 1.17 |
| Tax % | 16.67% | 38.57% | 50.68% | 27.17% | 32.68% | 22.47% | 26.19% | 32.14% | 27.27% | 21.55% | 32.74% | 26.50% |
| Net Profit | 0.35 | 0.43 | 0.35 | 0.66 | 1.03 | 0.69 | 0.31 | 0.19 | 0.80 | 0.91 | 1.53 | 0.86 |
| EPS in Rs | 8.37 | 10.29 | 8.37 | 15.79 | 24.64 | 10.29 | 0.41 | 0.25 | 1.06 | 1.21 | 2.03 | 1.14 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 22.86% | -18.60% | 88.57% | 56.06% | -33.01% | -55.07% | -38.71% | 321.05% | 13.75% | 68.13% | -43.79% |
| Change in YoY Net Profit Growth (%) | 0.00% | -41.46% | 107.18% | -32.51% | -89.07% | -22.06% | 16.36% | 359.76% | -307.30% | 54.38% | -111.92% |
Chandra Bhagat Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | -2% |
| 3 Years: | -3% |
| TTM: | -61% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 23% |
| 3 Years: | 2% |
| TTM: | -44% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 4% |
| 3 Years: | -23% |
| 1 Year: | -39% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 3% |
| 3 Years: | 4% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 2:51 pm
Balance Sheet
Last Updated: July 25, 2025, 1:36 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 0.67 | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 |
| Reserves | 5.55 | 5.98 | 6.33 | 6.99 | 8.03 | 13.78 | 18.14 | 18.33 | 19.13 | 19.93 | 21.46 | 22.42 |
| Borrowings | 18.58 | 27.50 | 27.83 | 22.08 | 21.75 | 31.22 | 29.93 | 27.07 | 21.11 | 18.94 | 16.43 | 20.86 |
| Other Liabilities | 7.07 | 8.39 | 9.91 | 26.40 | 27.86 | 37.19 | 19.12 | 18.83 | 24.68 | 14.16 | 56.37 | 50.70 |
| Total Liabilities | 31.62 | 42.29 | 44.49 | 55.89 | 58.06 | 82.86 | 74.74 | 71.78 | 72.47 | 60.58 | 101.81 | 101.53 |
| Fixed Assets | 1.02 | 0.87 | 0.69 | 0.55 | 0.51 | 0.46 | 0.44 | 0.42 | 0.47 | 0.73 | 2.52 | 2.62 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 4.64 | 1.05 | 4.03 | 0.75 | 0.00 | 0.22 | 0.11 | 0.13 | 0.14 |
| Other Assets | 30.60 | 41.42 | 43.80 | 50.70 | 56.50 | 78.37 | 73.55 | 71.36 | 71.78 | 59.74 | 99.16 | 98.77 |
| Total Assets | 31.62 | 42.29 | 44.49 | 55.89 | 58.06 | 82.86 | 74.74 | 71.78 | 72.47 | 60.58 | 101.81 | 101.53 |
Below is a detailed analysis of the balance sheet data for Chandra Bhagat Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 7.55 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 7.55 Cr..
- For Reserves, as of Mar 2025, the value is 22.42 Cr.. The value appears strong and on an upward trend. It has increased from 21.46 Cr. (Mar 2024) to 22.42 Cr., marking an increase of 0.96 Cr..
- For Borrowings, as of Mar 2025, the value is 20.86 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 16.43 Cr. (Mar 2024) to 20.86 Cr., marking an increase of 4.43 Cr..
- For Other Liabilities, as of Mar 2025, the value is 50.70 Cr.. The value appears to be improving (decreasing). It has decreased from 56.37 Cr. (Mar 2024) to 50.70 Cr., marking a decrease of 5.67 Cr..
- For Total Liabilities, as of Mar 2025, the value is 101.53 Cr.. The value appears to be improving (decreasing). It has decreased from 101.81 Cr. (Mar 2024) to 101.53 Cr., marking a decrease of 0.28 Cr..
- For Fixed Assets, as of Mar 2025, the value is 2.62 Cr.. The value appears strong and on an upward trend. It has increased from 2.52 Cr. (Mar 2024) to 2.62 Cr., marking an increase of 0.10 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.14 Cr.. The value appears strong and on an upward trend. It has increased from 0.13 Cr. (Mar 2024) to 0.14 Cr., marking an increase of 0.01 Cr..
- For Other Assets, as of Mar 2025, the value is 98.77 Cr.. The value appears to be declining and may need further review. It has decreased from 99.16 Cr. (Mar 2024) to 98.77 Cr., marking a decrease of 0.39 Cr..
- For Total Assets, as of Mar 2025, the value is 101.53 Cr.. The value appears to be declining and may need further review. It has decreased from 101.81 Cr. (Mar 2024) to 101.53 Cr., marking a decrease of 0.28 Cr..
Notably, the Reserves (22.42 Cr.) exceed the Borrowings (20.86 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -16.75 | -24.50 | -24.41 | -17.70 | -17.16 | -26.63 | -26.81 | -23.39 | -18.27 | -15.60 | -23.47 | -22.28 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 65.15 | 70.99 | 66.15 | 79.92 | 67.16 | 90.32 | 54.50 | 79.61 | 58.22 | 24.98 | 65.05 | 151.31 |
| Inventory Days | 161.44 | 176.71 | 122.83 | 132.66 | 144.60 | 173.53 | 186.75 | 214.70 | 153.25 | 99.59 | 15.23 | 3.44 |
| Days Payable | 53.01 | 43.18 | 32.81 | 80.69 | 68.58 | 117.37 | 53.13 | 78.51 | 11.98 | 10.62 | 23.21 | 44.58 |
| Cash Conversion Cycle | 173.59 | 204.52 | 156.17 | 131.89 | 143.18 | 146.48 | 188.12 | 215.80 | 199.49 | 113.95 | 57.06 | 110.17 |
| Working Capital Days | 148.78 | 166.47 | 133.63 | 124.96 | 138.50 | 83.39 | 147.60 | 177.18 | 103.94 | 75.00 | 35.89 | 115.28 |
| ROCE % | 11.68% | 10.44% | 10.40% | 14.77% | 17.42% | 13.13% | 6.97% | 7.44% | 8.62% | 7.13% | 7.95% | 6.00% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.14 | 2.03 | 1.20 | 1.06 | 0.25 |
| Diluted EPS (Rs.) | 1.14 | 2.03 | 1.20 | 1.06 | 0.25 |
| Cash EPS (Rs.) | 2.40 | 2.88 | 1.55 | 1.22 | 0.29 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 39.72 | 38.45 | 36.42 | 35.35 | 34.30 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 39.72 | 38.45 | 36.42 | 35.35 | 34.30 |
| Revenue From Operations / Share (Rs.) | 114.93 | 293.40 | 158.61 | 124.68 | 93.70 |
| PBDIT / Share (Rs.) | 5.39 | 5.69 | 4.79 | 5.69 | 1.05 |
| PBIT / Share (Rs.) | 4.13 | 4.84 | 4.44 | 5.53 | 1.01 |
| PBT / Share (Rs.) | 1.54 | 3.00 | 1.54 | 1.45 | 0.36 |
| Net Profit / Share (Rs.) | 1.14 | 2.03 | 1.20 | 1.05 | 0.25 |
| PBDIT Margin (%) | 4.68 | 1.93 | 3.01 | 4.56 | 1.12 |
| PBIT Margin (%) | 3.58 | 1.64 | 2.79 | 4.43 | 1.07 |
| PBT Margin (%) | 1.34 | 1.02 | 0.97 | 1.16 | 0.39 |
| Net Profit Margin (%) | 0.98 | 0.69 | 0.75 | 0.84 | 0.26 |
| Return on Networth / Equity (%) | 2.86 | 5.27 | 3.29 | 2.98 | 0.73 |
| Return on Capital Employeed (%) | 9.64 | 11.86 | 9.95 | 12.12 | 1.95 |
| Return On Assets (%) | 0.84 | 1.50 | 1.49 | 1.09 | 0.26 |
| Long Term Debt / Equity (X) | 0.07 | 0.04 | 0.14 | 0.20 | 0.36 |
| Total Debt / Equity (X) | 0.69 | 0.56 | 0.68 | 0.74 | 0.96 |
| Asset Turnover Ratio (%) | 0.85 | 2.73 | 1.80 | 1.30 | 0.96 |
| Current Ratio (X) | 1.41 | 1.38 | 2.19 | 1.86 | 2.13 |
| Quick Ratio (X) | 1.40 | 1.26 | 1.11 | 0.96 | 1.06 |
| Inventory Turnover Ratio (X) | 0.00 | 1.54 | 0.53 | 0.07 | 0.23 |
| Interest Coverage Ratio (X) | 2.09 | 3.09 | 1.65 | 1.40 | 1.65 |
| Interest Coverage Ratio (Post Tax) (X) | 1.44 | 2.10 | 1.41 | 1.26 | 1.39 |
| Enterprise Value (Cr.) | 59.68 | 83.14 | 85.69 | 99.92 | 52.54 |
| EV / Net Operating Revenue (X) | 0.68 | 0.37 | 0.71 | 1.06 | 0.74 |
| EV / EBITDA (X) | 14.68 | 19.38 | 23.71 | 23.26 | 66.02 |
| MarketCap / Net Operating Revenue (X) | 0.45 | 0.32 | 0.61 | 0.91 | 0.42 |
| Price / BV (X) | 1.32 | 2.47 | 2.66 | 3.22 | 1.15 |
| Price / Net Operating Revenue (X) | 0.45 | 0.32 | 0.61 | 0.91 | 0.42 |
| EarningsYield | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Chandra Bhagat Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 5. It has decreased from 2.03 (Mar 24) to 1.14, marking a decrease of 0.89.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 5. It has decreased from 2.03 (Mar 24) to 1.14, marking a decrease of 0.89.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.40. This value is below the healthy minimum of 3. It has decreased from 2.88 (Mar 24) to 2.40, marking a decrease of 0.48.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 39.72. It has increased from 38.45 (Mar 24) to 39.72, marking an increase of 1.27.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 39.72. It has increased from 38.45 (Mar 24) to 39.72, marking an increase of 1.27.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 114.93. It has decreased from 293.40 (Mar 24) to 114.93, marking a decrease of 178.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 5.39. This value is within the healthy range. It has decreased from 5.69 (Mar 24) to 5.39, marking a decrease of 0.30.
- For PBIT / Share (Rs.), as of Mar 25, the value is 4.13. This value is within the healthy range. It has decreased from 4.84 (Mar 24) to 4.13, marking a decrease of 0.71.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.54. This value is within the healthy range. It has decreased from 3.00 (Mar 24) to 1.54, marking a decrease of 1.46.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 2. It has decreased from 2.03 (Mar 24) to 1.14, marking a decrease of 0.89.
- For PBDIT Margin (%), as of Mar 25, the value is 4.68. This value is below the healthy minimum of 10. It has increased from 1.93 (Mar 24) to 4.68, marking an increase of 2.75.
- For PBIT Margin (%), as of Mar 25, the value is 3.58. This value is below the healthy minimum of 10. It has increased from 1.64 (Mar 24) to 3.58, marking an increase of 1.94.
- For PBT Margin (%), as of Mar 25, the value is 1.34. This value is below the healthy minimum of 10. It has increased from 1.02 (Mar 24) to 1.34, marking an increase of 0.32.
- For Net Profit Margin (%), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 5. It has increased from 0.69 (Mar 24) to 0.98, marking an increase of 0.29.
- For Return on Networth / Equity (%), as of Mar 25, the value is 2.86. This value is below the healthy minimum of 15. It has decreased from 5.27 (Mar 24) to 2.86, marking a decrease of 2.41.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.64. This value is below the healthy minimum of 10. It has decreased from 11.86 (Mar 24) to 9.64, marking a decrease of 2.22.
- For Return On Assets (%), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 5. It has decreased from 1.50 (Mar 24) to 0.84, marking a decrease of 0.66.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 0.2. It has increased from 0.04 (Mar 24) to 0.07, marking an increase of 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.69. This value is within the healthy range. It has increased from 0.56 (Mar 24) to 0.69, marking an increase of 0.13.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.85. It has decreased from 2.73 (Mar 24) to 0.85, marking a decrease of 1.88.
- For Current Ratio (X), as of Mar 25, the value is 1.41. This value is below the healthy minimum of 1.5. It has increased from 1.38 (Mar 24) to 1.41, marking an increase of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 1.40. This value is within the healthy range. It has increased from 1.26 (Mar 24) to 1.40, marking an increase of 0.14.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. It has decreased from 1.54 (Mar 24) to 0.00, marking a decrease of 1.54.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.09. This value is below the healthy minimum of 3. It has decreased from 3.09 (Mar 24) to 2.09, marking a decrease of 1.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.44. This value is below the healthy minimum of 3. It has decreased from 2.10 (Mar 24) to 1.44, marking a decrease of 0.66.
- For Enterprise Value (Cr.), as of Mar 25, the value is 59.68. It has decreased from 83.14 (Mar 24) to 59.68, marking a decrease of 23.46.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has increased from 0.37 (Mar 24) to 0.68, marking an increase of 0.31.
- For EV / EBITDA (X), as of Mar 25, the value is 14.68. This value is within the healthy range. It has decreased from 19.38 (Mar 24) to 14.68, marking a decrease of 4.70.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.45. This value is below the healthy minimum of 1. It has increased from 0.32 (Mar 24) to 0.45, marking an increase of 0.13.
- For Price / BV (X), as of Mar 25, the value is 1.32. This value is within the healthy range. It has decreased from 2.47 (Mar 24) to 1.32, marking a decrease of 1.15.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.45. This value is below the healthy minimum of 1. It has increased from 0.32 (Mar 24) to 0.45, marking an increase of 0.13.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chandra Bhagat Pharma Ltd:
- Net Profit Margin: 0.98%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.64% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 2.86% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.44
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.4
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 43.7 (Industry average Stock P/E: 50.21)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.69
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.98%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 323-F Bhagat Bhuvan, Mumbai Maharashtra 400019 | compliancecbc@gmail.com http://www.cbcpharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Hemant Chandravadan Bhagat | Chairman & Managing Director |
| Mr. Pranav Hemant Bhagat | Whole Time Director |
| Mrs. Prachi Pranav Bhagat | Director & CFO |
| Mr. Ravindra Gajanan Awati | Independent Director |
| Ms. Abha Praveen Doshi | Independent Director |
FAQ
What is the intrinsic value of Chandra Bhagat Pharma Ltd?
Chandra Bhagat Pharma Ltd's intrinsic value (as of 19 October 2025) is 34.12 which is 16.98% lower the current market price of 41.10, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 31.0 Cr. market cap, FY2025-2026 high/low of 80.0/0.00, reserves of ₹22.42 Cr, and liabilities of 101.53 Cr.
What is the Market Cap of Chandra Bhagat Pharma Ltd?
The Market Cap of Chandra Bhagat Pharma Ltd is 31.0 Cr..
What is the current Stock Price of Chandra Bhagat Pharma Ltd as on 19 October 2025?
The current stock price of Chandra Bhagat Pharma Ltd as on 19 October 2025 is 41.1.
What is the High / Low of Chandra Bhagat Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Chandra Bhagat Pharma Ltd stocks is 80.0/0.00.
What is the Stock P/E of Chandra Bhagat Pharma Ltd?
The Stock P/E of Chandra Bhagat Pharma Ltd is 43.7.
What is the Book Value of Chandra Bhagat Pharma Ltd?
The Book Value of Chandra Bhagat Pharma Ltd is 39.7.
What is the Dividend Yield of Chandra Bhagat Pharma Ltd?
The Dividend Yield of Chandra Bhagat Pharma Ltd is 0.00 %.
What is the ROCE of Chandra Bhagat Pharma Ltd?
The ROCE of Chandra Bhagat Pharma Ltd is 6.00 %.
What is the ROE of Chandra Bhagat Pharma Ltd?
The ROE of Chandra Bhagat Pharma Ltd is 2.41 %.
What is the Face Value of Chandra Bhagat Pharma Ltd?
The Face Value of Chandra Bhagat Pharma Ltd is 10.0.